美托洛尔联合阿托伐他汀钙片治疗冠心病合并急性心力衰竭的效果分析

TAnalysis of the Effect of Metoprolol Combined with Atorvastatin Calcium in the Treatment of Coronary Heart Disease Complicated with Acute Heart Failure

目的分析美托洛尔联合阿托伐他汀钙治疗冠心病心衰患者的临床效果。方法回顾性分析2022年6月至2024年3月河南科技大学第一附属医院收治的96例冠心病合并急性心力衰竭患者的临床资料,其中45例给予美托洛尔治疗的患者纳入对照组,其余给予美托洛尔联合阿托伐他汀钙片联合治疗的51例患者纳入观察组,比较两组临床疗效、心功能指标、心衰标志物和心肌酶指标水平差异,评价患者用药安全性。结果观察组治疗有效率(86.27%)高于对照组(68.89%),差异有统计学意义(P<0.05)。治疗前,两组心功能指标、心衰标志物和心肌酶指标水平相比差异无统计学意义(P>0.05);治疗后,观察组左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、肌酸激酶同工酶(CK-MB)、B型尿钠肽(BNP)和肌钙蛋白Ⅰ(cTnⅠ)均低于对照组,左室射血分数(LVEF)和心肌肌钙蛋白T(cTnT)高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率相比差异无统计学意义(P>0.05)。结论美托洛尔和阿托伐他汀钙联合治疗可以有效改善冠心病合并急性心力衰竭患者的心功能,减轻患者的心肌损伤,具有较高安全性和有效性,临床应用价值显著。

Objective To analyze the clinical effect of metoprolol combined with atorvastatin calcium in patients with coronary heart disease(CHD)and acute heart failure(AHF).Methods A retrospective analysis was conducted on the clinical data of 96 patients with CHD and AHF who were treated at the First Affiliated Hospital of Henan University of Science and Technology from June 2022 to March 2024.Among these patients,45 received metoprolol treatment and were included in the control group,while the remaining 51 received a combination of metoprolol and atorvastatin calcium tablets and were included in the observation group.The clinical efficacy,cardiac function indicators,heart failure biomarkers,and myocardial enzyme levels were compared between the two groups to evaluate the safety of the treatment.Results The effective rate in the observation group(86.27%)was significantly higher than that in the control group(68.89%),with statistical significance(P<0.05).Before treatment,there were no significant differences in cardiac function indicators,heart failure biomarkers,and myocardial enzyme levels between the two groups(P>0.05).After treatment,the observation group showed significantly lower levels of left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),creatine kinase-MB(CK-MB),B-type natriuretic peptide(BNP),and cardiac troponin I(cTnI)compared to the control group,while left ventricular ejection fraction(LVEF)and cardiac troponin T(cTnT)were higher,with statistical significance(P<0.05).The incidence of adverse reactions was not significantly different between the two groups(P>0.05).Conclusion The combination of metoprolol and atorvastatin calcium can effectively improve cardiac function and reduce myocardial injury in patients with CHD and AHF,with high safety and efficacy,demonstrating significant clinical application value.